This study investigates the recurrence-free survival in people with cutaneous squamous cell carcinoma (cSCC). Recurrence-free survival means the length of time after treatment during which the cancer does not return. The study compares those who receive an investigational medication with those who receive a placebo as additional therapy after primary treatment. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine.
Participants in the study will be randomly assigned to one of two study arms. One arm will receive the investigational medication, and the other will receive a placebo. The study will involve regular assessments by the investigator, including biopsy confirmation, to monitor the status of the cancer.
- Who can participate: Adults with confirmed cutaneous squamous cell carcinoma, who are disease-free as assessed by the investigator, can participate. They must have completed radiographic staging assessment within 28 days before joining the study.
- Study details: Participants will be assigned to receive either the investigational medication or a placebo. They will undergo regular assessments, including biopsy, to confirm the status of their cancer.
